US 12,263,209 B2
Pharmaceutical compositions comprising collagenase I and collagenase II
Wayne K. Herber, Coopersburg, PA (US)
Assigned to ENDO BIOLOGICS LIMITED, (IE)
Filed by Endo Biologics Limited, Dublin (IE)
Filed on Oct. 25, 2024, as Appl. No. 18/927,301.
Application 15/669,286 is a division of application No. 14/328,772, filed on Jul. 11, 2014, granted, now 9,757,435, issued on Sep. 12, 2017.
Application 18/927,301 is a continuation of application No. 18/615,520, filed on Mar. 25, 2024.
Application 18/615,520 is a continuation of application No. 16/816,097, filed on Mar. 11, 2020, granted, now 11,975,054, issued on May 7, 2024.
Application 16/816,097 is a continuation of application No. 15/669,286, filed on Aug. 4, 2017, granted, now 10,603,365, issued on Mar. 31, 2020.
Application 14/328,772 is a continuation of application No. PCT/US2013/020940, filed on Jan. 10, 2013.
Claims priority of provisional application 61/585,909, filed on Jan. 12, 2012.
Prior Publication US 2025/0041391 A1, Feb. 6, 2025
Int. Cl. A61K 38/48 (2006.01); C12N 9/52 (2006.01); A61K 38/16 (2006.01); C12N 9/50 (2006.01); C12Q 1/37 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01)
CPC A61K 38/4886 (2013.01) [C12N 9/52 (2013.01); C12Y 304/24003 (2013.01); A61K 38/164 (2013.01); C12N 9/50 (2013.01); C12Q 1/37 (2013.01); G01N 33/5044 (2013.01); G01N 33/56911 (2013.01); G01N 2333/96419 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A pharmaceutical composition comprising,
collagenase I purified from a host cell comprising a vector, the vector comprising a recombinant nucleic acid molecule comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO: 5 and a heterologous regulatory sequence operably linked to the polynucleotide; and
collagenase II purified from a host cell comprising a vector, the vector comprising a recombinant nucleic acid molecule comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO: 6 and a heterologous regulatory sequence operably linked to the polynucleotide;
wherein the collagenase I and collagenase II are present in a ratio of about 1 to 1 and the composition is free of hemolytic toxins as measured by a hemolysis assay.